Differential effects of mental stress on plasma homovanillic acid in schizophrenia and normal controls

Neuropsychopharmacology

Volumn 20, Issue 4, 1999, Pages 365-369

  Sumiyoshi, Tomiki ^a   Saitoh, Osamu ^a   Yotsutsuji, Takashi ^a   Itoh, Hiroko ^a   Kurokawa, Kenzo ^a   Kurachi, Masayoshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Dopamine restitutive system; Kraepelin test; Mental stress; pHVA; Plasma homovanillic acid; Schizophrenia

Indexed keywords

HOMOVANILLIC ACID; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARITHMETIC; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL STRESS; MENTAL TEST; NORMAL HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; HOMOVANILLIC ACID; HUMANS; MALE; REFERENCE VALUES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STRESS, PSYCHOLOGICAL;

EID: 0032983835     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00095-5     Document Type: Article

References (32)

1. Akiyama K., Tsuchida K., Kanzaki A., Ujike H., Hamamura T., Kondo K., Mutoh S., Miyanagi K., Kuroda S., Otsuki S. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics. Comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance Biol Psychiatry. 38:1995;639-648.
2. Chang W.-H., Hwu H.-G., Chen T.-Y., Lin S.-K., Lung F.-W., Chen H., Lin W.-L., Hu W.-H., Lin H.-N., Chien C.-P. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients. Schizophr Res. 10:1993;259-265.
3. Csernansky J.G., Barnes D.E., Bellows E.P., Lombrozo L. Interrelationships between plasma homovanillic acid and indices of dopamine turnover in multiple brain areas during haloperidol and saline administration. Life Sci. 46:1990;707-713.
4. Davilia R., Manero E., Zumarraga M., Andia I., Schweitzer J.W., Friedhoff A.J. Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry. 45:1988;564-567.
5. Davis K.L., Davidson M., Mohs R.C., Kendler K.S., David B.M., Johns C.A., DeNigris Y., Horvath T.B. Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science. 227:1985;1601-1602.
6. Deutch A.Y., Clark W.A., Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 521:1990;311-315.
7. Doran A., Picker D., Labarca R., Douillet R., Wolkowitz O., Thomas J., Roy A., Dane S. Evidence for a daily rhythm of plasma HVA in normal controls but not in schizophrenic patients. Psychopharmacol Bull. 21:1985;694-697.
8. Friedhoff A.J. Restitutive processes in the regulation of behavior. Alpert M. Controversies in Schizophrenia. Change and Constancies:1985;137-144 Guilford Press, New York.
9. Friedhoff AJ (1986): A dopamine-dependent restitutive system for the maintenance of mental normalcy. In Burrell CD, Strand FL (eds), Second Colloquium in Biological Sciences. New York, Ann NY Acad Sci 463:860-864.
10. Friedhoff A.J. Dopamine as a mediator of a central stabilizing system. Neuropsycopharmacology. 1:1988;189-191.
11. Friedhoff A.J., Carr K.D., Uysal S., Schweitzer J. Repeated inescapable stress produces a neuroleptic-like effect on the conditioned avoidance response. Neuropsychopharmacology. 13:1995;129-138.
12. Friedhoff A.J., Amin F. Plasma Homovanillic Acid in Schizophrenia. Implication for Presynaptic Dopamine Dysfunction:1997;American Psychiatric Press, Washington, DC.
13. Garver D.L., Steinberg J.L., McDermott B.E., Yao J.K., Ramberg J.E., Lewis S., Kingsbury S.J. Etiologic heterogeneity of the psychoses. Is there a dopamine psychosis? Neuropsychopharmacology. 16:1997;191-201.
14. Green A.I., Alam M.Y., Boshes R.A., Waternaux C., Pappalardo K.M., Fitzgibbon M.E., Tsuang M.T., Schildkraut J.J. Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res. 10:1993;33-37.
15. Kopin I.J., Bankiewicz K.S., Harvey-White J. Assessment of brain dopamine metabolism from plasma HVA and MHPG during debisoquin treatment. Validation in monkeys treated with MPTP Neuropsychopharmacology. 1:1988;119-125.
16. Koreen A.R., Lieberman J., Alvir J., Mayerhoff D., Loebel A., Chakos M., Amin F., Copper T. Plasma homovanillic acid levels in first-episode schizophrenia. Arch Gen Psychiatry. 51:1994;132-138.
17. Kuraishi S., Kato M., Tsujioka B. Development of the "Uchida-Kraepelin psychodiagnostic test" in Japan. Psychologia. 1:1957;104-109.
18. Lambert G.W., Eisenhofer G., Cox H.S., Horne M., Kalff V., Kelly M., Jennings G.L., Esler M.D. Direct determination of homovanillic acid release from the human brain, an indicator of central dopaminergic activity. Life Sci. 49:1991;1061-1072.
19. Lambert G.W., Eisenhofer G., Jennings G.L., Esler M.D. Regional homovanillic acid production in human. Life Sci. 53:1993;63-75.
20. Maas J.W., Contreras S.A., Miller A.L., Berman N., Bowden C.L., Javor M.A., Seleshi E., Weintraub S. Studies on catecholamine metabolism in schizophrenia/psychosis-1. Neuropsychopharmacology. 8:1993;97-109.
21. Maas J.W., Contreras S.A., Seleshi E., Bowden C.L. Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin sulfate Arch Gen Psychiatry. 45:1988;553-559.
22. Nagaoka S., Iwamoto N., Arai H. First-episode neuroleptic-free schizophrenics. Concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment Biol Psychiatry. 41:1997;857-864.
23. Pickar D., Labarca R., Linnoila M., Roy A., Hommer D., Everett D., Paul S.M. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science. 225:1984;954-957.
24. Reynolds G.P. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature. 305:1983;527-529.
25. Seeman P., Guan H.-C., Van Tol H.H.M. Dopamine D4 receptors elevated in schizophrenia. Nature. 365:1993;441-445.
26. Steinberg J.L., Graver D.L., Moeller F.G., Raese J.D., Orsulak P.J. Serum homovanillic acid levels in schizophrenic patients and normal control subjects. Psychiatry Res. 48:1993;93-106.
27. Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer H.Y. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls. Relation to neuroleptic resistance Biol Psychiatry. 41:1997;560-566. a.
28. Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer H.Y. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Res. 69:1997;113-121. b.
29. Sumiyoshi T., Yotsutsuji M., Kurachi M., Itoh H., Kurokawa K., Saitoh O. Effect of mental stress on plasma homovanillic acid levels in healthy subjects. Soc Neurosci Abstr. 23:1997;2036. c.
30. Sumiyoshi T., Yotsutsuji T., Kurachi M., Itoh H., Kurokawa K., Saitoh O. Effect of mental stress on plasma homovanillic acid in healthy human subjects. Neuropsychopharmacology. 19:1998;70-73.
31. Whelton C.L., Gupta R.N., Cleghorn J.M., Ballagh S.R. Influence of renal clearance on peripheral homovanillic acid measurements in healthy subjects and schizophrenic patients. Schizophr Res. 11:1993;33-40.
32. Wong D.F., Wagner H.N., Tune L.E., Dannals R.F., Pearlsson G.D., Links J.M., Tamminga C.A., Broussolle E.P., Ravert H.T., Wilson A.A., Toung J.K.F., Malat J., Williams F.A., O'Touma L.A., Snyder S.H., Kuhar M.J., Gjedde A. Positron emission tomography reveals elevated D2-dopamine receptors in drug-naive schizophrenia. Science. 234:1986;1558-1563.